Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 8;14(12):2829.
doi: 10.3390/cancers14122829.

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives

Mathieu Césaire  1   2 , Juliette Montanari  2 , Hubert Curcio  3 , Delphine Lerouge  3 , Radj Gervais  3 , Pierre Demontrond  3 , Jacques Balosso  1 , François Chevalier  2
Affiliations
Review

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives

Mathieu Césaire et al. Cancers (Basel). .

Abstract

Survival in unresectable locally advanced stage non-small cell lung cancer (NSCLC) patients remains poor despite chemoradiotherapy. Recently, adjuvant immunotherapy improved survival for these patients but we are still far from curing most of the patients with only a 57% survival remaining at 3 years. This poor survival is due to the resistance to chemoradiotherapy, local relapses, and distant relapses. Several biological mechanisms have been found to be involved in the chemoradioresistance such as cancer stem cells, cancer mutation status, or the immune system. New drugs to overcome this radioresistance in NSCLCs have been investigated such as radiosensitizer treatments or immunotherapies. Different modalities of radiotherapy have also been investigated to improve efficacity such as dose escalation or proton irradiations. In this review, we focused on biological mechanisms such as the cancer stem cells, the cancer mutations, the antitumor immune response in the first part, then we explored some strategies to overcome this radioresistance in stage III NSCLCs with new drugs or radiotherapy modalities.

Keywords: cancer mutation; cancer stem cell; immunotherapy; non-small-cell lung cancer; proton irradiation; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. [(accessed on 2 December 2020)]; Available online: https://pubmed.ncbi.nlm.nih.gov/25220842/ - PubMed
    1. Aupérin A., Le Péchoux C., Rolland E., Curran W.J., Furuse K., Fournel P., Belderbos J., Clamon G., Ulutin H.C., Paulus R., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 2010;28:2181–2190. doi: 10.1200/JCO.2009.26.2543. - DOI - PubMed
    1. Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K.H., De Wit M., et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 2017;377:1919–1929. doi: 10.1056/NEJMoa1709937. - DOI - PubMed
    1. Gray J.E., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K.H., Cho B.C., et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. [(accessed on 2 December 2020)]; Available online: https://pubmed.ncbi.nlm.nih.gov/31622733/ - PMC - PubMed
    1. Oberije C., De Ruysscher D., Houben R., van de Heuvel M., Uyterlinde W., Deasy J., Belderbos J., Dingemans A.-M.C., Rimner A., Din S., et al. A Validated prediction model for overall survival from stage III non-small cell lung cancer: Toward survival prediction for individual patients. Int. J. Radiat. Oncol. Biol. Phys. 2015;92:935–944. doi: 10.1016/j.ijrobp.2015.02.048. - DOI - PMC - PubMed

LinkOut - more resources